Dual action of ketamine confines addiction liability

This study in mice shows that ketamine does increase dopamine levels in the brain (nucleus accumbens) but doesn’t lead to synaptic plasticity (e.g. as seen with cocaine). Thus, the addiction liability of ketamine is (relatively) limited (not taking into account social factors).

Abstract

“Ketamine is used clinically as an anaesthetic and a fast-acting antidepressant, and recreationally for its dissociative properties, raising concerns of addiction as a possible side effect. Addictive drugs such as cocaine increase the levels of dopamine in the nucleus accumbens. This facilitates synaptic plasticity in the mesolimbic system, which causes behavioural adaptations and eventually drives the transition to compulsion. The addiction liability of ketamine is a matter of much debate, in part because of its complex pharmacology that among several targets includes N-methyl-D-aspartic acid (NMDA) receptor (NMDAR) antagonism. Here we show that ketamine does not induce the synaptic plasticity that is typically observed with addictive drugs in mice, despite eliciting robust dopamine transients in the nucleus accumbens. Ketamine nevertheless supported reinforcement through the disinhibition of dopamine neurons in the ventral tegmental area (VTA). This effect was mediated by NMDAR antagonism in GABA (γ-aminobutyric acid) neurons of the VTA, but was quickly terminated by type-2 dopamine receptors on dopamine neurons. The rapid off-kinetics of the dopamine transients along with the NMDAR antagonism precluded the induction of synaptic plasticity in the VTA and the nucleus accumbens, and did not elicit locomotor sensitization or uncontrolled self-administration. In summary, the dual action of ketamine leads to a unique constellation of dopamine-driven positive reinforcement, but low addiction liability.”

Authors: Linda D. Simmler, Yue Li, Lotfi C. Hadjas, Agnès Hiver, Ruud van Zessen & Christian Lüscher

Become a psychedelic insider!

With a free Blossom membership you will always be in the know.

📰 Weekly newsletter about the psychedelic research

✔️ Unlimited access to our database and original articles

🖊️ Add (private) notes and comments to each page

Make an account

Find this paper

Dual action of ketamine confines addiction liability

https://doi.org/10.1038/s41586-022-04993-7

Paywall | Google Scholar | Backup | 🕊

Published in
Nature
July 27, 2022
0 citations

Study details

Compounds studied
Ketamine

Topics studied
Safety

Study characteristics
Animal Study Bio/Neuro